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Introduction: Thymic carcinoma is a rare epithelial neoplasm that
tends to be aggressive and metastasize widely. The optimal chemo-
therapy for unresectable advanced thymic carcinoma has not yet
been established because of its rare occurrence. The purpose of this
study was to evaluate the efficacy and tolerability of combination
chemotherapy with doxorubicin, vincristine, cyclophosphamide, and
platinum compounds for advanced thymic carcinoma.
Methods: A retrospective analysis of 34 patients with untreated and
unresectable thymic carcinoma who received chemotherapy with doxo-
rubicin, vincristine, cyclophosphamide, and platinum compounds be-
tween 1996 and 2010 was conducted. Twenty-nine patients were
treated with a combination of cisplatin (50 mg/m2) and doxorubicin (40
mg/m2) on day 1, vincristine (0.6 mg/m2) on day 3, and cyclophosph-
amide (700 mg/m2) on day 4. Five patients were treated with carbo-
platin (area under the curve of 3.0 minutes  mg/ml) instead of cisplatin.
Results: The responses of all 34 patients to the current regimen were
assessed. The median number of treatment cycles for the present
chemotherapy was 4. The overall response rate and disease control rate
were 50.0% and 88.2%, respectively. The median survival was 21.3
months (95% confidence interval [CI], 15.0–37.2 months), and the
1-year and 3-year survival rates were 72.7% (95% CI, 56.8–88.6%)
and 34.4% (95% CI, 16.2–52.6%), respectively. The most common
adverse event was leukopenia/neutropenia, and nonhematological tox-
icities were mild.
Conclusions: Combination chemotherapy with doxorubicin, vin-
cristine, cyclophosphamide, and platinum compounds is an ef-
fective and well-tolerated treatment for unresectable advanced
thymic carcinoma.
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Thymic carcinoma is a rare epithelial neoplasm with ma-lignant cytologic features, and it accounts for approxi-
mately 5 to 36% of all thymic epithelial tumors.1–3 The
clinical course of thymic carcinoma tends to be much more
aggressive than that of thymoma, and thymic carcinoma also
tends to metastasize widely, which results in poor out-
come.2–7 Therefore, although systemic chemotherapy could
play an important role in the treatment of thymic carcinoma,
the optimal regimen has not been established because of the
rare occurrence of this malignancy. There are few reports
describing possible chemotherapy strategies for advanced
thymic carcinoma, and these are based on small series and/or
retrospective studies.8–16 These reports have indicated that
thymic carcinoma is relatively sensitive to chemotherapy, and
cisplatin-based chemotherapies have shown promising results
in certain patients with advanced thymic carcinoma. Yoh et
al.12 evaluated the efficacy of CODE (cisplatin, vincristine,
doxorubicin, and etoposide) therapy in 12 patients with thy-
mic carcinoma and reported a response rate (RR) of 41.7%.
Igawa et al.14 also reported the efficacy of carboplatin plus
paclitaxel therapy in 11 patients with a RR of 36.4%.
Combination chemotherapy with cisplatin, doxorubi-
cin, vincristine, and cyclophosphamide (ADOC) was initially
reported for the treatment of invasive thymoma. Fornasiero et
al.17 administered ADOC chemotherapy to 37 patients with
unresectable invasive thymoma and reported a RR of 91.8%
and a 43% complete remission. Meanwhile, Koizumi et al.11
described eight cases with thymic carcinoma treated with
ADOC chemotherapy and reported a RR of 75%. In addition,
Kitami et al.10 reported that all four cases who received modified
ADOC (nedaplatin, doxorubicin, vincristine, and cyclophosph-
amide) chemotherapy obtained partial responses (PRs).
This study is a retrospective analysis of 34 patients with
unresectable thymic carcinoma who received chemotherapy
with doxorubicin, vincristine, cyclophosphamide, and platinum
compounds in our hospital in the first-line setting. In this study, the
efficacy and the tolerability of this combination chemotherapy for
the treatment of advanced thymic carcinoma were assessed.
PATIENTS AND METHODS
A total of 38 consecutive patients with thymic carci-
noma were admitted to the Respiratory Division of Shinshu
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University hospital from August 1996 to March 2010. All
patients were histologically diagnosed as thymic carcinoma
based on the World Health Organization (WHO) criteria.18
The histological samples were obtained by percutaneous
computed tomography-guided biopsy, video-assisted thoracic
surgery, or cervical lymph node biopsy. All patients had local
invasion and/or distant metastasis at the time of presentation
and were considered to have stage IVa or IVb disease
according to Masaoka’s classification.19 Thirty-four of 38
patients were previously untreated and received systemic
chemotherapy as the first-line treatment as described later. A
physical examination, complete blood cell count, biochemis-
try examination, chest radiography, computed tomography
scans of the thorax and abdomen, a bone scintigraphy or F-18
fluorodeoxyglucose positron emission tomography, and mag-
netic resonance imaging scan of the brain were performed for
all patients as a pretreatment evaluation. Before the chemo-
therapy, written informed consent was obtained from all the
subjects.
The combination chemotherapy with cisplatin (50 mg/m2)
and doxorubicin (40 mg/m2) on day 1, vincristine (0.6 mg/m2)
on day 3, and cyclophosphamide (700 mg/m2) on day 4, which
is termed ADOC chemotherapy, was performed in 29 pa-
tients. Five patients were treated with carboplatin (area under
the curve of 3.0 minutes  mg/ml) instead of cisplatin because
of insufficient renal function, poor performance status (PS),
or advanced age. All drugs were administered intravenously,
and dexamethasone (8 mg) and/or granisetron (3 mg) were
administered for the prevention of emesis induced by the
chemotherapy. This regimen was repeated every 3 to 4 weeks
and continued to the maximum of six cycles, if the tumor
responded to the treatment and the toxicities were acceptable.
Granulocyte colony stimulating factor was used as treatment
for neutropenia but was not used routinely as a prophylactic
treatment. Subsequent doses of the anticancer drugs were
modified on the basis of hematological and nonhematological
toxicities at the discretion of the physician in charge. If the
patient’s condition allowed it, second-line and further treat-
ments after the current chemotherapy were also performed at
the discretion of the attending physician.
The response to chemotherapy was evaluated using the
WHO standard response criteria20 in patients who were
treated by 2002 and the RECIST21 in patients from 2003
onward. The overall survival time was measured from the
first day of the treatment with the current combination che-
motherapy to the date of death or last follow-up. Fisher’s
exact test was applied to compare RRs between cisplatin and
carboplatin groups. The survival curves were calculated using
the Kaplan–Meier method22 and compared among responses
to the chemotherapy with the log-rank test. A p value of less
than 0.05 was considered statistically significant. All statis-
tical analyses were performed using MedCalc version 11.4.4
(MedCalc Software, Mariakerke, Belgium).
Toxicities associated with chemotherapy were graded
according to the WHO criteria23 in patients treated by 1999,
the National Cancer Institute-Common Toxicity Criteria ver-
sion 2.024 in patients from 2000 to 2004, and the Common
Terminology Criteria for Adverse Events version 3.025 in
patients from 2005 onward.
RESULTS
Patient Characteristics
The characteristics of 34 patients are listed in Table 1.
Twenty-two patients were men, and 12 women, with median
age of 56 years (range, 36–82 years). Twenty-eight patients
(82.4%) had PS of 0 or 1 according to the Eastern Coopera-
tive Oncology Group scale.26 Histological subtypes of thymic
carcinoma in the current patients were squamous cell carci-
noma in 25 patients (73.5%), small cell carcinoma in two
patients (5.9%), large cell neuroendocrine carcinoma in one
patient (2.9%), and undifferentiated carcinoma in six patients
(17.6%). The diagnoses of the three patients with small cell
carcinoma or large cell neuroendocrine carcinoma were based
on the radiographic and bronchoscopic findings with absence
of intrapulmonary and lymph node lesions. Twelve patients
(35.3%) had stage IVa disease, and 22 (64.7%) stage IVb
disease, according to Masaoka’s classification.19
Response to Chemotherapy and Survival
The median number of treatment cycles was 4 (range,
1–6 cycles, Table 1). The responses of the 34 patients to the
current chemotherapy are listed in Table 2. PR was achieved
in 17 patients, 13 patients showed stable disease (SD), and
only four patients demonstrated progressive disease (PD).
The overall RR and disease control rate (DCR) were 50.0%
and 88.2%, respectively. Three patients were treated with
radical surgical resection following the current treatment
TABLE 1. Patient Characteristics












Squamous cell carcinoma 25






Cycles of the current therapy delivered
Median 4
Range 1–6
ECOG, Eastern Cooperative Oncology Group; LCNEC, large cell neuroendocrine
carcinoma.
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regimen based on favorable tumor reduction in response to
chemotherapy.
The median follow-up time was 35.5 months (range,
6.2–96.5 months). Figure 1 shows the overall survival curve
for 34 patients. The median survival time (MST) was 21.3
months (95% confidence interval [CI], 15.0–37.2 months).
The 1- and 3-year survival rates were estimated at 72.7%
(95% CI, 56.8–88.6%) and 34.4% (95% CI, 16.2–52.6%),
respectively. When the patients were grouped according to
the responses to chemotherapy, the MSTs in patients who
achieved PR, who demonstrated SD, and who exhibited PD
were 25.3 months (95% CI, 11.2–53.0 months), 37.2 months
(95% CI, 15.0–111.5 months), and 8.1 months (95% CI,
2.0–23.8 months), respectively (Figure 2). The survival times
in the PR and SD groups were significantly superior to those
of the PD group (PR versus PD; p  0.0197, SD versus PD;
p  0.0199). There were no statistical differences in the
survival times between the PR and SD groups (p  0.3007).
The RR and DCR in the 29 patients who received cisplatin
were 55.2% and 89.7%, respectively. Of the five patients who
received carboplatin instead of cisplatin, one patient achieved
PR and three exhibited SD. Among the five patients, the RR was
20.0% and the DCR was 80.0%. The survival curves of both
groups are shown in Figure 3. The MSTs in cisplatin and
carboplatin group were 23.8 months (95% CI, 15.0–47.6
months) and 7.7 months (95% CI, 2.0–32.3 months), respec-
tively. Although the RR, DCR, and survival time in the
cisplatin group showed a favorable tendency compared with
those in the carboplatin group, there were no statistical
differences, respectively (RR, p 0.3328; DCR, p 0.8945;
and survival time, p  0.2000).
Toxicities
The main toxicities of the current chemotherapy in the
34 patients are summarized in Table 3. Grade 3 or 4 leuko-
penia and neutropenia were observed in 24 patients (70.6%)
and 26 patients (76.5%), respectively. There were no patients
with grade 3 or more severe anemia. Grade 3 thrombocyto-
penia was observed in one patient (2.9%). Although four
patients (11.8%) developed febrile neutropenia, they were
successfully treated with antibiotics and granulocyte colony
stimulating factor. The most common nonhematological tox-
FIGURE 1. Overall survival curve for the 34 patients in-
cluded in the study. The median survival time was 21.3
months.
TABLE 2. Responses to Chemotherapy with Doxorubicin,
Vincristine, Cyclophosphamide, and Platinum Compounds
No. of Patients Percentage
Complete response 0 0
Partial response 17 50.0
Stable disease 13 38.2
Progressive disease 4 11.8
FIGURE 2. Comparison among survival curves of patients
who demonstrated PR, SD, and PD. There were significant
differences between PR and SD (p  0.0197) and between
SD and PD (p  0.0199). PR, partial response; SD, stable
disease; PD, progressive disease.
FIGURE 3. Comparison among survival curves of patients
who received cisplatin and carboplatin. There was no signifi-
cant difference between the cisplatin and carboplatin groups
(p  0.2000).
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icity was anorexia, which was observed in eight patients
(23.5%) with a grade of 3. Grade 3 nausea and vomiting were
seen in seven (20.6%) and two patients (5.9%), respectively.
Those symptoms improved in a short period after the completion
of chemotherapy in most of the patients. Overall, the nonhema-
tological toxicities were regarded as mild. There were no treat-
ment-related deaths with the current chemotherapy.
DISCUSSION
The present report describes the efficacy and toxicities
of combination chemotherapy with doxorubicin, vincristine,
cyclophosphamide, and platinum compounds in 34 patients
with unresectable advanced thymic carcinoma. Data on che-
motherapy regimens for the treatment of advanced thymic
carcinoma are limited, and a standard treatment regimen
therefore remains to be established. To the best of our
knowledge, the current report is the largest series study
analyzing chemotherapy strategies for thymic carcinoma.
With respect to studies on more than 10 patients with
thymic carcinoma to evaluate the efficacy of a single regi-
men, there are currently only two retrospective reports.12,14 A
study evaluating CODE chemotherapy in 12 patients reported
a RR of 41.7% and MST of 46 months,12 and in another
study, combination chemotherapy with carboplatin plus pac-
litaxel in 11 patients had a RR of 36.4% and MST of 22.7
months.14 There are no published prospective studies de-
signed exclusively for patients with thymic carcinoma, and
only two reports addressing thymic tumors (thymoma and
thymic carcinoma) are available in the current literature.15,16
In addition, the two existing reports included a small number
of patients with thymic carcinoma (seven and eight patients,
respectively). Therefore, the evaluation of chemotherapy for
advanced thymic carcinoma based on previous reports is
difficult. In this study, combination chemotherapy with doxo-
rubicin, vincristine, cyclophosphamide, and platinum com-
pounds in 34 patients with advanced thymic carcinoma dem-
onstrated a RR of 50.0%. This result could be equivalent or
superior to CODE chemotherapy12 and to carboplatin plus
paclitaxel chemotherapy.14 Although the MST in CODE
chemotherapy was reported to be 46 months,12 the MST in
this study was 21.3 months. This difference might be partly
due to the predominance of patients with stage IVb disease in
our study.
Four patients exhibited PD in this study. After the
completion of the chemotherapy series, two patients received
the best supportive care because of a deterioration of PS.
Sequential radiation was given to two other patients after PD,
and only one patient achieved PR as best response. Besides,
these two patients received other chemotherapies after the
radiotherapy but could not achieve PR in any regimens.
Based on these results, thymic carcinoma showing resistance
to the current chemotherapy regimen may also show resis-
tance against other chemotherapies. Thus, the poor response
to chemotherapy with doxorubicin, vincristine, cyclophosph-
amide, and platinum compounds might be predictive of
reduced chemosensitivity in patients with advanced thymic
carcinoma.
Five patients who received carboplatin instead of cis-
platin showed a relatively lower RR and shorter MST, com-
pared with patients treated with cisplatin. The median age of
the patients in the carboplatin group was 79 years (range,
71–82 years). Two patients had a PS of 2, and four patients
had stage IVb disease. These factors might influence the RR
and MST, which could explain the differences observed
between the two groups. In addition, because of the small
number of patients, a comparison between the efficacy of
carboplatin and cisplatin is not possible. Differences in the
anticancer activity of these two agents in thymic carcinoma
need to be investigated further.
With respect to adverse events, although the current
regimen showed mild gastrointestinal toxicity, leukopenia
and neutropenia were frequently seen. In a study of the
efficacy of ADOC chemotherapy in 37 patients with invasive
thymoma reported by Fornasiero et al.,17 70% of patients
developed grade 3 nausea/vomiting according to WHO cri-
teria,23 with 22% of patients showing grade 3 leukopenia.
These results were regarded as opposite to the present results.
The differences in gastrointestinal toxicities might be due to
differences in the administration of antiemetics, e.g., steroids
and 5-hydroxytryptamine 3 receptor antagonists. The differ-
ences in hematological toxicities might be related to the age
of the patients; the median age in this study was 56 years, and
in the study by Fornasiero et al.,17 it was 40 years. In this
study, although leukopenia/neutropenia was the most com-
mon adverse event, febrile neutropenia was observed in as
few as 11.8%, and there were no treatment-related deaths.
The present treatment, therefore, proved to be a well-tolerated
chemotherapy regimen.
Meanwhile, it is the age of personalized medicine in the
treatment strategies for advanced malignancies today. Tar-
geted therapies for the treatment of thymic carcinoma have
been described in some case reports and small case series.27,28
Successful treatments with sorafenib29,30 and sunitinib31 for
the patients with chemotherapy-resistant advanced thymic
carcinoma have been reported, and a phase II study evaluat-
ing the combination of cetuximab with chemotherapy is
ongoing in patients with thymoma. Thus, the combination of
the current regimen with these molecular targeted agents may
bring further benefit to patients with advanced thymic carci-
TABLE 3. Toxicities of Chemotherapy with Doxorubicin,
Vincristine, Cyclophosphamide, and Platinum Compounds
Grade 3 Grade 4 >3 (%)
Hematological toxicities
Leukopenia 19 5 70.6
Neutropenia 12 14 76.5
Anemia 0 0 0
Thrombocytopenia 1 0 2.9
Nonhematological toxicities
Febrile neutropenia 4 0 11.8
Nausea 7 0 20.6
Vomiting 2 0 5.9
Anorexia 8 0 23.5
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noma. On the other hand, predictive molecular markers in the
treatment for thymic carcinoma should also be examined.
In conclusion, combination chemotherapy with doxo-
rubicin, vincristine, cyclophosphamide, and platinum com-
pounds is a promising treatment strategy for unresectable
advanced thymic carcinoma and can be considered an effec-
tive regimen for this condition. Nevertheless, similar to the
previous reports,10,11 the present report is also based on a
retrospective study, and a definitive conclusion can only be
reached through prospective studies. Because of the low
incidence rates of this type of carcinoma, the results of this
study indicate that multicenter clinical trials of this chemo-
therapy for unresectable advanced thymic carcinoma are
warranted.
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